2323623-93-2

AS-99 is a first-in-class, potent, and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 μM, Kd= 0.89 μM) with anti-leukemic activity, blocking cell proliferation, inducing apoptosis and differentiation, downregulating MLL fusion target genes, and reducing the leukemia burden in vivo[1].

AS-99 TFA is a potent, and selective ASH1L histone methyltransferase inhibitor with an IC50 of 0.79 μM. It exhibits robust anti-leukemic activity by blocking cell proliferation, inducing apoptosis and differentiation. AS-99 TFA exerts its effects by downregulating MLL fusion target genes and has been shown to significantly reduce leukemia burden in vivo.

AS-99 is a first-in-class, potent, and selective inhibitor of the ASH1L histone methyltransferase, displaying anti-leukemic activity with an IC50 of 0.79 µM and a Kd of 0.89 µM. It inhibits cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and effectively reduces leukemia burden [in vivo].